key: cord-1045083-ba72qq7w
authors: Iwamuro, Ayumi; Sasa, Tomoki; Kawai, Takafumi; Taguchi, Mamoru; Izuhara, Masayasu; Uegaito, Takashi; Shioji, Keisuke
title: A 17-year-old male with acute myocarditis following mRNA-1273 vaccination in Japan
date: 2022-04-26
journal: J Cardiol Cases
DOI: 10.1016/j.jccase.2022.03.012
sha: 9da5a5c44052931c1f830b1fc3ec614501b336c6
doc_id: 1045083
cord_uid: ba72qq7w

Vaccinations are the main tool being used to control the COVID-19 pandemic. When the Japanese Ministry of Health approved the Moderna mRNA-1273 vaccination in May 2021, it was limited to patients over 18 years old; however, using the additional data of efficacy and safety from clinical trials, vaccination was approved for 12- to 17-year-olds in Japan in July 2021. A previous study reported that myocarditis after the mRNA-1273 vaccination was more prevalent in young men; however, no patients under 18 years old with myocarditis diagnosed by cardiovascular magnetic resonance (CMR) findings after mRNA-1273 vaccination have been reported in Japan. In the present case, a 17-year-old healthy male developed arthralgia and had fever on the day of the second mRNA-1273 vaccination for severe acute respiratory syndrome coronavirus 2. Three days after the vaccination, the patient felt severe chest pain with broad ST elevations on electrocardiography and troponin T elevations. Symptoms and findings rapidly improved; however, on CMR, myocarditis remained. Thus, it is necessary to be vigilant of potential acute myocarditis in young men following mRNA-1273 vaccination. LEARNING OBJECTIVE: Although it is very rare, acute myocarditis after mRNA-1273 (Moderna) vaccination developed within 3–5 days following the second dose of the vaccine. Most reported cases were mild or moderate in severity, but there were cases of cardiogenic shock. We need to be vigilant of acute myocarditis in young men following mRNA-1273 vaccination.

Vaccinations are the main tool being used to control the COVID-19 pandemic. When the Japanese Ministry of Health approved the Moderna mRNA-1273 vaccination in May 2021, it was limited to patients over 18 years old; however, using the additional data of efficacy and safety from clinical trials, vaccination was approved for 12-to 17year-olds in Japan in July 2021. Myocarditis after mRNA-1273 vaccination has been reported [1] . Furthermore, a study reported that postvaccine myocarditis was more prevalent in young men [2] . Acute myocarditis after mRNA-1273 vaccination in children under 18 years old is rare (28.8 per million people as previously reported by the Japanese Ministry of Health [www.mhlw.go.jp, p. 49]).

We present a case of acute myocarditis after mRNA-1273 vaccination in a 17-year-old patient, including cardiovascular magnetic resonance (CMR) imaging findings.

A 17-year-old healthy male developed arthralgia and a fever of 38°C on the day of the second dose of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) vaccine (Moderna). He presented to a clinic 3 days after vaccination with sharp substernal severe chest pain. Physical examination revealed a fever of 37.7°C, blood pressure of 121/64 mmHg, pulse of 71/min, and oxygen saturation of 98% on room air. As electrocardiography (ECG) revealed sinus rhythm and broadly obvious ST elevations with no reciprocal changes ( Fig. 1) , he was transferred to our hospital. Initial laboratory results showed an elevated troponin T (TnT) of 0.327 ng/m (normal range: <0.014 ng/ml), creatine kinase of 337 U/L (normal range: 59-248 U/L), and high creactive protein (CRP) of 1.87 mg/ml (normal range: <0.14 mg/ml) with normal NTproBNP of 99.4 pg/ml (normal range: 0-125 pg/ml). His liver and renal functions were normal. A nasopharyngeal SARS-Journal of Cardiology Cases xxx (xxxx) xxx Cov-2 antigen test was negative. Transthoracic echocardiography demonstrated normal ventricle wall thickness, normal chamber size, normal systolic function, and normal volume of pericardial effusion. We did not test for viruses that cause myocarditis. We diagnosed acute myocarditis due to mRNA-1273 vaccination based on his background, clinical course, ECG, and echocardiography. The patient was admitted to our hospital for observation and was treated with acetaminophen for 3 days until the fever subsided.

CMR was performed 4 days after vaccination to clarify the myocardial damage (Fig. 2) . Cine imaging showed normal left ventricular size, wall thickness, and contraction without pericardial effusion. T2weighted imaging revealed increased bright signal intensity in the apical anterior wall, which indicated myocardial edema ( Fig. 2A) . Late gadolinium enhancement CMR imaging showed focal late enhancement in the same lesion with non-ischemic regional distribution, which indicated myocarditis (Fig. 2B) . Using the 2018 Lake Louise criteria [3] , these findings were consistent with a diagnosis of acute myocarditis. After 2 days in hospital, his fever had subsided and his TnT and CRP had normalized. He was discharged without complications.

At the outpatient checkup one month later, his ECG findings, TnT, CRP, and NTproBNP were normalized, and exercise tolerance was maintained with AT-VO2 of 113% in the cardiopulmonary exercise stress test.

We present a 17-year-old male with acute myocarditis after mRNA-1273 vaccination, including CMR imaging findings. The patient had typical symptoms with ECG changes on the third day after the vaccination. Thus, we diagnosed the patient as having developed myocarditis three days after the second vaccination. His symptoms rapidly improved. A previous study reported that most cases of myocarditis developed within a few days after the second dose of vaccine [4] .

In a previous study of patients (n = 136) with definite or probable myocarditis in Israel, 19 patients presented after the first dose of vaccine and 117 patients after the second dose [4] . A previous study reported that most cases of myocarditis were mild or moderate in severity; however, there were cases of cardiogenic shock [2] . Multisystem inflammatory syndrome in children (MISC) has been reported, which is a serious condition that appears to be linked to COVID-19 vaccination [5] . This patient had fever for 3 days and developed myocarditis, but did not have any other organ abnormalities and did not go into shock; thus, he did not meet the diagnostic criteria for MISC. Most cases of MISC develop within 2-6 weeks; thus, patients with post-vaccine myocarditis should be monitored for several months after the onset of the disease.

Young patients with mild or moderate chest pain may not seek medical attention. Thus, subclinical myocarditis may occur and be detectable by active surveillance. The primary concern of clinicians is not the incidence of serious side effects of vaccines, but the likelihood of outcomes, such as myocardial damage, in the patients that they treat.

Although the benefits of vaccines outweigh the risks, our findings suggest that myocarditis may occur after mRNA-1273 vaccination in young men.

The authors declare that there is no conflict of interest.

Patients with acute myocarditis following mRNA COVID-19 vaccination

Myocarditis after Covid-19 vaccination in a large health care organization

Comparison of original and 2018 Lake Louise criteria for diagnosis of acute myocarditis: results of a validation cohort

Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel

Multisystem inflammatory syndrome after SARS-CoV-2 infection and COVID-19 vaccination